ClinicalTrials.gg
CompletedNCT00593281INFUSEUpdated Jan 14, 2008

INFUSE Morphine Study

A Phase 3 interventional study of Hylenex in Pain, sponsored by Halozyme Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-01-14.

Sponsored by Halozyme Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,882 studies in Pain with a site in United States — 313 open to participants now, 392 under way, 24 of them phase 3. Pain · United States.

Enrollment
2,222nd of 2,560
13 · median 66
Started
2006
with 106 others
Phase 3
343 of 2,882
17 open now
Registered
393rd of 2,882
by date

Among the 2,882 studies in Pain with a site in United States, this one is the 2,222nd largest by enrollment of the 2,560 interventional ones that give a count, is one of 107 that started in 2006, is one of 343 in phase 3, and was the 393rd registered.

Pain

10,066 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

313 of the 2,882 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

308 more — sign in →

All 313 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,882 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

Double-blind study comparing the pharmacokinetics, safety and tolerability of morphine administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX) and intravenously conducted in patients in a hospice care setting or through a palliative care medicine setting. In this within-patient controlled study, each eligible study patient receives a single injection by each of the three methods of morphine administration, sequentially on three consecutive days, according to the order specified by a randomization schedule.

Each of the three injections consists of 5 mg of morphine (1.0 mL of 5 mg/mL solution). The HYLENEX injection will be 1 mL of 150 units. Although the IV administration will not be blinded, the two SC injections will be double-blinded, using the same volume of normal saline (0.9% sodium chloride) placebo (1.0 mL) as HYLENEX.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Hyaluronidase
  • Hylenex
  • subcutaneous
  • morphine
  • absorption
  • bioavailability
  • PK study of morphine in patients with pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females at least 18 years of age who are patients of San Diego Hospice \& Palliative Care or recruited through San Diego Hospice \& Palliative Care or the UCSD Center for Pain and Palliative Medicine.
  2. During the treatment days of the study, on opioid therapy other than morphine that is equivalent to ≥ 60 mg oral morphine per day and without unacceptable toxicity.
  3. Vital signs (BP, HR, RR) within normal range.
  4. Adequate venous access in both upper extremities.
  5. A negative pregnancy test (if female of ) within 7 days prior to first injection.
  6. ≥ ten days.
  7. Decision-making capacity.
  8. Signed, written IRB-approved . -

Exclusion criteria

Exclusion Criteria:

  1. Known or history of any toxicity to morphine.
  2. Morphine within the 4 days prior to the first study medication injection or anticipated to be receiving morphine during any of the treatment days in this study.
  3. Any to morphine.
  4. Known hypersensitivity to naloxone.
  5. Known allergy to hyaluronidase or any other ingredient in the formulation of HYLENEX.
  6. Known allergy to bee or vespid venom.
  7. Contraindication to IV heparin lock or known hypersensitivity to heparin.
  8. Edema, infection, or any other lower extremity or pelvic disorder that might affect subcutaneous absorption from the thigh.
  9. \< 10 g/dL.
  10. Presence of any other medical condition that would present an unacceptable safety risk to the patient.
  11. Participation in a study of any drug or device within 30 days of enrollment in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
13 participants (actual)

Study arms

  • No intervention
    1

    IV Morphine

  • Experimental
    2

    SC Morphine with Hylenex

    Drug: Hylenex

  • Active comparator
    3

    SC Morphine with Saline

    Drug: Hylenex

Interventions

  • Add Hylenex to SC injection of Morphine

06

What researchers measure

Primary outcomes

  1. • Determine the Tmax and other pharmacokinetic parameters of morphine injected subcutaneously with HYLENEX compared to without HYLENEX and injected intravenously

    Time frame: 29 days

Secondary outcomes

  1. Compare the safety and tolerability of these three methods of injections of morphine

    Time frame: 29 days

07

Study locations

2 sites
  • UCSD Thornton Hospital
    San Diego, California 92037, United States
  • San Diego Hospice and Palliative Care
    San Diego, California 92103, United States
08

References and documents

Publications

  • Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage. 2009 Nov;38(5):663-72. doi: 10.1016/j.jpainsymman.2009.03.009. Epub 2009 Oct 12. PubMed 19819665 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2008
First posted
Jan 14, 2008
Start
Jan 2006
Primary completionActual
Oct 2006
CompletionActual
Oct 2006
Last update
Jan 14, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00593281
First posted
Jan 14, 2008
Start date
Jan 2006
Primary completion
Oct 2006
Completion
Oct 2006
Last update
Jan 14, 2008

Study contacts

Jay Thomas, M.D.
principal investigator · San Diego Hospice
Mark S Wallace, M.D.
principal investigator · UCSD Thornton Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronidase (human recombinant)

Start the discussion